Skip to main content
. 2021 Jan 21;1(1):100005. doi: 10.1016/j.xagr.2021.100005

Table 2.

Distribution of person-centered maternity care subscale scores at baseline and maternal and newborn health outcomes measured at follow-up by total person-centered maternity care score

Characteristic Total (N=1014) Total PCMC score
Low (n=251) Medium (n=485) High (n=278)
Dignity and respect subscale score
 Low 203 (20.0) 153 (61.9) 50 (10.3) 0 (0.0)
 Medium 556 (54.8) 92 (37.3) 349 (71.8) 115 (40.9)
 High 255 (25.2) 2 (0.8) 87 (17.9) 166 (59.1)
Communication and autonomy subscale score
 Low 257 (25.4) 183 (74.1) 74 (15.2) 0 (0.0)
 Medium 500 (49.3) 64 (25.9) 364 (74.9) 72 (25.6)
 High 257 (25.4) 0 (0.0) 48 (9.9) 209 (74.4)
Supportive care subscale score
 Low 248 (24.5) 194 (78.5) 48 (9.9) 0 (0.0)
 Medium 450 (44.4) 53 (21.5) 336 (69.1) 57 (20.3)
 High 316 (31.2) 0 (0.0) 102 (21.0) 224 (79.7)
Maternal complications reported at either follow-up
 No 873 (86.1) 204 (82.6) 417 (85.8) 252 (89.7)
 Yes 141 (13.9) 43 (17.4) 69 (14.2) 29 (10.3)
Screened positive for depression at either follow-up
 No 845 (83.3) 186 (75.3) 410 (84.4) 249 (88.6)
 Yes 169 (16.7) 61 (24.7) 76 (15.6) 32 (11.4)
Adopted family planning method by 10 wk follow-up
 No 571 (56.3) 152 (61.5) 272 (56.0) 147 (52.3)
 Yes 443 (43.7) 95 (38.5) 214 (44.0) 134 (47.7)
Exclusive breastfeeding at 10 wk follow-upa
 No 151 (18.0) 40 (20.1) 75 (18.7) 36 (15.0)
 Yes 690 (82.0) 159 (79.9) 327 (81.3) 204 (85.0)
Newborn complications reported at either follow-up
 No 687 (67.8) 148 (59.9) 336 (69.1) 203 (72.2)
 Yes 327 (32.3) 99 (40.1) 150 (30.9) 78 (27.8)
Returned to a facility for newborn immunizations by 10 wk follow-up
 No 404 (39.8) 104 (42.1) 190 (39.1) 110 (39.2)
 Yes 610 (60.2) 143 (57.9) 296 (60.9) 171 (60.9)

Data are presented as number (percentage). Percentages may not add to 100 because of rounding.

PCMC, person-centered maternity care.

Sudhinaraset. Person-centered maternity care associated with maternal and newborn health. Am J Obstet Gynecol Glob Rep 2021.

a

Sample size, N=841 (women who completed baseline and 10 weeks follow-up).